ArticleCureus2026
Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown robust efficacy in glycemic control, weight reduction, and cardiovascular protection, but concerns remain regarding rare adverse events such as acute pancreatitis. We report a 59-year-old man with type 2 diabetes, stage IIIA colon cancer post-hemicolectomy and chemotherapy, stage 4 chronic kidney disease, hypertension, and dyslipidemia who developed acute pancreatitis after 2.5 years of weekly semaglutide therapy. He presented with epigastric pain and elevated lipase, while abdominal ultrasound revealed only mild pancreatic parenchymal heterogeneity without peripancreatic fluid collection. The patient improved with conservative management, and semaglutide was discontinued in favor of linagliptin, with no recurrence of symptoms during three months of follow-up. This case highlights the potential risk of pancreatitis in patients with multimorbidity, a population frequently excluded from randomized controlled trials and underrepresented in real-world prescribing due to socioeconomic barriers. Clinicians should remain vigilant when prescribing semaglutide to patients with multiple underlying chronic conditions, and further studies focusing on multimorbid populations are warranted to clarify its safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.